Dr. Maurizio Zanetti Joins InNexus Biotechnology Scientific Advisory Board.BRITISH COLUMBIA, Canada -- InNexus Biotechnology Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :IXSBF) (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension VENTURE:IXS (Integrated XSeries Server) An x86-based xSeries server (motherboard and memory) from IBM that plugs into an iSeries or i5 midrange computer. Running Windows or Linux, the IXS shares disk storage, server management, user administration with its iSeries/i5 host. ), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL (Domino eXtensible Language) A version of XML for Domino-based data. An XSLT processor is used to convert DXL data to XML data for external use. See Lotus Notes. [TM]) technology, today announced that Maurizio Zanetti, M.D., Professor with the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. , Department of Medicine, Tumor Growth, Invasion & Metastatis Program, has joined the InNexus Scientific Advisory Board. Dr. Zanetti joins Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation The Oklahoma Medical Research Foundation (OMRF), located in Oklahoma City, Oklahoma, is an independent, nonprofit biomedical research institute. Established in 1946, OMRF is dedicated to understanding and developing more effective treatments for human disease. Stephen M. and InNexus SAB Chairman, Dr. John D. Minna, Dr. Carlos L. Arteaga, Dr. Ellen Vitetta, Dr. Martin Weigert and Dr. Judith James. Welcoming Dr. Zanetti, Dr. J. Donald Capra, InNexus SAB Chairman said, "Dr. Zanetti's extensive experience, expertise and distinguished career makes him another superb addition to the InNexus team. His tremendous efforts within cancer, tumor targeting and cancer vaccines is a compelling determinant of the opportunities science has to develop solutions for hard to treat diseases. Join me in welcoming him aboard and we look forward to his immediate contribution." Dr. Zanetti is a member of UCSD's Cancer Center and the Center for Aids Research. Between 1982 - 2000 Dr. Zanetti was a Career Scientist of INSERM INSERM Institut National de la Santé et de la Recherche Médicale (French Institute of Health and Medical Research) (National Institute of Medical Research) of France and an Assistant Member, Division of Immunology, Medical Biology Institute, La Jolla, CA. Dr. Zanetti has belonged to numerous Honorary and Professional organizations, including Associate Editor, The Journal of Immunology The Journal of Immunology (The JI) is an academic journal that publishes basic and clinical studies in all aspects of immunology. It is owned and published by The American Association of Immunologists. Having an impact factor of 6. ; Associate Editor, Cellular Immunology; Member, American Society of Clinical Investigation; Member, Clinical Immunology Society. He has written over 150 books and publications spanning the years. About InNexus InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL[TM]) technology improving the potency of existing antibody products while opening new markets and disease applications. DXL[TM] antibodies utilize unique, novel and patented methods and technologies of InNexus. InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development facilities provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit www.ixsbio.com The TSX Venture Exchange TSX Venture Exchange Originally called the Canadian Venture Exchange (CDNX), this was a result of the merger of the Vancouver and Alberta stock exchanges. The goal of TSX Venture Exchange is to provide venture companies with effective access to capital while protecting investors. has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, that may cause actual results or performance to differ materially from those currently anticipated in such statements. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion